Advanced Biomedical Technologies

Advanced Biomedical Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Advanced Biomedical Technologies (ABMT) as of Oct 8, 2026 is -91.67 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 80.22 % — a change of -214.27% (lower).

FCF Conversion

-91.67 %

YoY

-214.27%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Advanced Biomedical Technologies is 2020 -91.67 % . FCF Conversion Rate (FCF/EBITDA) of Advanced Biomedical Technologies was 2019 80.22 % . It decreases by -214.27% lower compared to the previous year.

The Advanced Biomedical Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
98.82 USD
Jan 1, 2016
51.52 USD
Jan 1, 2017
80.71 USD
Jan 1, 2018
94.07 USD
Jan 1, 2019
80.22 USD
Jan 1, 2020
-91.67 USD
The Advanced Biomedical Technologies FCF Conversion history
YEARFCF ConversionYoY
-91.67 %-214.27%
80.22 %-14.73%
94.07 %+16.56%
80.71 %+56.65%
51.52 %-47.86%
98.82 %—
Access this data via the Eulerpool API

Advanced Biomedical Technologies Stock analysis

What does Advanced Biomedical Technologies do? Advanced Biomedical Technologies Inc is an innovative biomedical company specializing in the development of advanced medical devices and technologies. The company was founded in 1985 by an experienced team of biotech experts and is headquartered in California, USA. History: The company's roots lie in the research and development of novel medical implants and prosthetics. However, over the years, the company has quickly evolved into a leading provider of medical devices and technologies in the fields of diagnostics, therapy, and care. Business model: The business model of Advanced Biomedical Technologies Inc is focused on providing innovative and advanced solutions for medical care. The company strives to continuously develop its products and help customers achieve their healthcare goals. Divisions: The company is divided into four main divisions focusing on different medical areas: 1) Interventional Cardiology: Here, the company develops devices for the treatment of heart diseases, such as stents for reopening narrowed vessels. 2) Orthopedics: Another focus is on the development of innovative orthopedic implants and prosthetics that help patients regain their mobility and improve their quality of life. 3) Oncology: In this division, the company works on the development of medical devices and systems for the diagnosis and treatment of cancer. 4) Neurology: Here, the company focuses on the development of medical technologies and devices for the diagnosis and treatment of nervous system disorders, such as Parkinson's or Alzheimer's. Products: Advanced Biomedical Technologies Inc's products include a variety of medical devices and technologies specialized in different medical areas. Some of the company's most well-known products are: - Stents for reopening narrowed vessels in the heart - Artificial joints and implants for restoring mobility and quality of life - Medical devices for the diagnosis and treatment of cancer - Neurostimulation devices for the treatment of chronic pain and other neurological disorders - Robot-assisted surgery systems that assist surgeons in complex procedures. Conclusion: Advanced Biomedical Technologies Inc is a leading biomedical company specializing in the development of advanced medical devices and technologies. The company has a long history in the research and development of medical implants and prosthetics but has quickly expanded into a broader range of medical applications. With its focus on developing innovative products for patients' quality of life, Advanced Biomedical Technologies Inc will continue to play an important role in medical innovation. Advanced Biomedical Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Advanced Biomedical Technologies stock

FCF Conversion Rate (FCF/EBITDA) of Advanced Biomedical Technologies is -91.67 % in 2020.

FCF Conversion Rate (FCF/EBITDA) of Advanced Biomedical Technologies changed from 80.22 % to -91.67 %, representing a -214.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Advanced Biomedical Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Advanced Biomedical Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Advanced Biomedical Technologies

All Key Metrics — Advanced Biomedical Technologies